Meanwhile, these findings suggested that its role as a biomarker was particularly significant in certain cancers, such as lung cancer and melanoma, where high PLEK2 levels correlate strongly with poorer clinical outcomes and reduced immunotherapy response. This evidence concerns the gene PLEK2 and melanoma.